Detalhe da pesquisa
1.
Nanotechnology Applications in Breast Cancer Immunotherapy.
Small
; : e2308639, 2023 Dec 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38126905
2.
Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.
Cancer Metastasis Rev
; 40(2): 519-536, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33963482
3.
Targeted Nanoparticle for Co-delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis.
Small
; 18(11): e2107550, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35083840
4.
Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer.
Adv Funct Mater
; 25(18): 2646-2659, 2015 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-26097445
5.
Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment.
Nat Commun
; 13(1): 4261, 2022 07 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35871223
6.
Stimuli-responsive mesoporous silica nanoparticles: A custom-tailored next generation approach in cargo delivery.
Mater Sci Eng C Mater Biol Appl
; 124: 112084, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33947574
7.
In Situ Tumor Vaccination with Nanoparticle Co-Delivering CpG and STAT3 siRNA to Effectively Induce Whole-Body Antitumor Immune Response.
Adv Mater
; 33(31): e2100628, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34118167
8.
siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion.
Transl Res
; 214: 105-120, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31487500
9.
PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer.
Cancer Lett
; 467: 9-18, 2019 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31563561
10.
Removal of a gadolinium based contrast agent by a novel sorbent hemoperfusion in a chronic kidney disease (CKD) rodent model.
Sci Rep
; 9(1): 709, 2019 01 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30679698
11.
Lanthanide-Loaded Nanoparticles as Potential Fluorescent and Mass Probes for High-Content Protein Analysis.
Bioengineering (Basel)
; 6(1)2019 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30875927
12.
Selective capture of radionuclides (U, Pu, Th, Am and Co) using functional nanoporous sorbents.
J Hazard Mater
; 366: 677-683, 2019 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30580142
13.
Lyophilization and stability of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for siRNA delivery.
Int J Nanomedicine
; 13: 4015-4027, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30022824
14.
Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment.
PLoS One
; 13(6): e0198141, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29879129
15.
Oxidative stress in cancer and fibrosis: Opportunity for therapeutic intervention with antioxidant compounds, enzymes, and nanoparticles.
Redox Biol
; 11: 240-253, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28012439
16.
Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform.
Mol Cancer Ther
; 16(4): 763-772, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28138033
17.
Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment.
Cancer Treat Rev
; 45: 19-29, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26930249
18.
Therapeutic siRNA for drug-resistant HER2-positive breast cancer.
Oncotarget
; 7(12): 14727-41, 2016 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26894975
19.
Erratum to "siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion" [Translational Research 214C (2019) 105-120].
Transl Res
; 217: 77, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32081297
20.
Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis.
Biomaterials
; 66: 41-52, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26196532